CARDIOVASCULAR INFLAMMATION REDUCTION TRIAL (CIRT) STUDY

NewYork-Presbyterian Queens is looking for individuals to take part in a clinical research study who have coronary artery disease. Patients treated for coronary artery disease suffer the high risk of having a heart attack or suffering a stroke and this is related to high levels of inflammation in the blood vessels.  The CIRT Study will show if reducing inflammation can lower the risk of having a future heart attack, a stroke, or dying from heart disease.

To enroll in the study, researchers at NYP Queens are seeking men and women who have had a heart attack or have major blockages in more than one coronary artery diagnosed in the past and have been diagnosed with either diabetes or metabolic syndrome. Interested individuals can see if they qualify for enrollment by calling Susan Ingenito at the Theresa and Eugene M. Lang Center for Research and Education at NYP/Queens, at 718-670-2414.

During the five-year study, participants receive special packs which contain study medications and be closely monitored by the study team for safety. Participants should continue to see their regular health care providers during this study.

NYP Queens is one of investigative sites for this study. Todd Kerwin, Director of Non-Invasive Cardiology, Division of Cardiology at NYP Queens is also a co-investigator in the study.

Cardiovascular Inflammation Reduction Trial (CIRT) for Cardiovascular Inflammation Reduction (ClinicalTrials.gov number: NCT01594333) is sponsored by Brigham and Women's Hospital.

CIRT